deflazacort (emflaza) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by suppressing inflammatory response.   NCATS

Chemistry

  • SMILES: CC1=N[C@@]2([C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)O1)C(=O)CO
  • InChIKey: KENSGCYKTRNIST-RVUAFKSESA-N
  • Mol. Mass: 399.4801
  • ALogP: 2.56
  • ChEMBL Molecule:
    deflazacort  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$33.2574 - $185.3143
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(11 beta,16 beta)-21-(acetyloxy)-11-hydroxy-2'- methyl-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20- dione | azacort | azacortinol | calcort | deflazacort | dezacor | dezacort | emflaza | flantadin | lantadin | mdl-458 | oxazacort | zamene

Organizations (21)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Immune System Diseases

Muscular Dystrophy, Duchenne

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Aspergillosis, Allergic Bronchopulmonary (Phase 2/Phase 3)

Atrophy (Phase 2/Phase 3)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Muscular Dystrophies, Limb-Girdle (Phase 3)

Muscular Dystrophy, Duchenne ()

Musculoskeletal Diseases (Phase 2/Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Tooth Abnormalities (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue